BERLIN, May 05, 2025--(BUSINESS WIRE)--Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment ...

For the second year in a row, the pharmaceutical industry has dipped further out of favor with patient groups around the world. The industry’s reputation surged during the COVID-19 pandemic ...

Pharmaceutical manufacturing encompasses all processes involved in the manufacturing and production of biological and medical products, botanical drugs, and herbs, as well as other pharmaceutical ...

Like his Big Pharma peers, Pfizer (PFE) CEO Albert Bourla is waiting for the US government to finalize its decision on whether to place a 25% tariff on pharmaceutical imports. To be sure ...

Another Big Pharma is opening up its wallet to pour billions into its U.S. operations amid political pressure from the Trump administration. This time it’s Gilead coming to the table with a ...

Innocan's first fully-granted patent in Mexico Covers Innocan's proprietary cannabis-based pain relief topical Indication of Innocan's growing intellectual property portfolio This patent covers a ...

TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME ...

HERZLIYA, Israel and CALGARY, AB, May 6, 2025 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer ...

BridgeBio Pharma BBIO is gearing up to announce its quarterly earnings on Tuesday, 2025-04-29. Here's a quick overview of what investors should know before the release. Analysts are estimating ...

Trump’s threat of pharma tariffs marks a fresh development in the president’s aggressive trade agenda. On Sunday, he threatened to impose 100% tariffs on foreign-made films.

AcelRx Pharmaceuticals (NASDAQ:TLPH) is scheduled to announce Q1 earnings results on Tuesday, May 13th, after market close. The consensus EPS Estimate is -$0.14 (+12.5% Y/Y) and the consensus Revenue ...

"We are excited to enter the next phase of Ousia Pharma's journey, advancing our groundbreaking platform towards clinical development," said Anders B. Klein, PhD, CEO of Ousia Pharma. "The strong ...